These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
346 related items for PubMed ID: 10347332
1. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Nørgaard BL, Wachtell K, Christensen PD, Madsen B, Johansen JB, Christiansen EH, Graff O, Simonsen EH. Am Heart J; 1999 Jun; 137(6):1062-9. PubMed ID: 10347332 [Abstract] [Full Text] [Related]
2. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Bianconi L, Castro A, Dinelli M, Alboni P, Pappalardo A, Richiardi E, Santini M. Eur Heart J; 2000 Aug; 21(15):1265-73. PubMed ID: 10924317 [Abstract] [Full Text] [Related]
3. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. Falk RH, Pollak A, Singh SN, Friedrich T. J Am Coll Cardiol; 1997 Feb; 29(2):385-90. PubMed ID: 9014993 [Abstract] [Full Text] [Related]
4. Dofetilide: a review of its use in atrial fibrillation and atrial flutter. McClellan KJ, Markham A. Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390 [Abstract] [Full Text] [Related]
5. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RC, Meissner MC, Zoble RG, Wakefield LK, Perry KT, Vanderlugt JT. J Am Coll Cardiol; 1996 Jul; 28(1):130-6. PubMed ID: 8752805 [Abstract] [Full Text] [Related]
7. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Pedersen OD, Bagger H, Keller N, Marchant B, Køber L, Torp-Pedersen C. Circulation; 2001 Jul 17; 104(3):292-6. PubMed ID: 11457747 [Abstract] [Full Text] [Related]
8. Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease. Banchs JE, Baquero GA, Nickolaus MJ, Wolbrette DL, Kelleman JJ, Samii S, Grando-Ting J, Penny-Peterson E, Davidson WR, Young SK, Naccarelli GV, Gonzalez MD. Congenit Heart Dis; 2014 Jul 17; 9(3):221-7. PubMed ID: 23947935 [Abstract] [Full Text] [Related]
9. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group. Frost L, Mortensen PE, Tingleff J, Platou ES, Christiansen EH, Christiansen N. Int J Cardiol; 1997 Jan 31; 58(2):135-40. PubMed ID: 9049678 [Abstract] [Full Text] [Related]
10. Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter. Lindeboom JE, Kingma JH, Crijns HJ, Dunselman PH. Am J Cardiol; 2000 Apr 15; 85(8):1031-3. PubMed ID: 10760352 [No Abstract] [Full Text] [Related]
11. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation. Coleman CI, Sood N, Chawla D, Talati R, Ghatak A, Kluger J, Dofetilide and Intravenous Magnesium Evaluation (DIME) Investigators. Europace; 2009 Jul 15; 11(7):892-5. PubMed ID: 19351630 [Abstract] [Full Text] [Related]
12. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Circulation; 1996 Oct 01; 94(7):1613-21. PubMed ID: 8840852 [Abstract] [Full Text] [Related]
13. Dofetilide: a new class III antiarrhythmic agent. Roukoz H, Saliba W. Expert Rev Cardiovasc Ther; 2007 Jan 01; 5(1):9-19. PubMed ID: 17187453 [Abstract] [Full Text] [Related]
14. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. Piccini JP, Pritchett EL, Davison BA, Cotter G, Wiener LE, Koch G, Feld G, Waldo A, van Gelder IC, Camm AJ, Kowey PR, Iwashita J, Dittrich HC. Heart Rhythm; 2016 Sep 01; 13(9):1777-83. PubMed ID: 27108936 [Abstract] [Full Text] [Related]
15. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Stambler BS, Wood MA, Ellenbogen KA. Circulation; 1997 Dec 16; 96(12):4298-306. PubMed ID: 9416896 [Abstract] [Full Text] [Related]
16. Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter. Banchs JE, Wolbrette DL, Samii SM, Penny-Peterson ED, Patel PP, Young SK, Gonzalez MD, Naccarelli GV. J Interv Card Electrophysiol; 2008 Nov 16; 23(2):111-5. PubMed ID: 18688699 [Abstract] [Full Text] [Related]
19. A Quarter of a Century Later: What is Dofetilide's Clinical Role Today? Wolbrette DL, Hussain S, Maraj I, Naccarelli GV. J Cardiovasc Pharmacol Ther; 2019 Jan 21; 24(1):3-10. PubMed ID: 29940780 [Abstract] [Full Text] [Related]